The Collaborative Ocular Tuberculosis Study (COTS) calculator-a consensus-based decision tool for initiating antitubercular therapy in ocular tuberculosis.


Journal

Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986

Informations de publication

Date de publication:
05 2023
Historique:
received: 04 03 2022
accepted: 14 06 2022
revised: 15 05 2022
pmc-release: 01 05 2024
medline: 11 5 2023
pubmed: 29 6 2022
entrez: 28 6 2022
Statut: ppublish

Résumé

To introduce the Collaborative Ocular Tuberculosis Study (COTS) Calculator, an online clinical scoring system for initiating antitubercular therapy (ATT) in patients with ocular tuberculosis (TB). The COTS Calculator was derived from COTS Consensus (COTS CON) data, which has previously published consensus guidelines. Using a two-step Delphi method, 81 experts evaluated 486 clinical scenario-based questions, ranking their likelihood of initiating ATT in each specific scenario. Each scenario was a permutation of the results and/or availability of five following components-clinical phenotype, endemicity, two immunological (tuberculin skin test, interferon-γ release assay) and one radiological (chest X-Ray) test results-and a sixth component further stratifying three of the clinical phenotypes. The median scores and interquartile ranges (IQR) of each scenario were tabulated, representing the expert consensus on whether to initiate ATT in that scenario. The consensus table was encoded to develop the COTS Calculator. The COTS Calculator can be accessed online at: https://www.oculartb.net/cots-calc . The attending physician can select the conditions present in the patient, which will generate a median score from 1 to 5. 114 out of 486 scenarios (24%) deliberated had a median score of 5 indicating expert consensus to initiate ATT. The COTS Calculator is an efficient, low-cost, evidence and experience-based clinical tool to guide ATT initiation. While it holds substantial promise in improving standard-of-care for ocular-TB patients, future validation studies can help to as certain its clinical utility and reliability.

Identifiants

pubmed: 35764876
doi: 10.1038/s41433-022-02147-7
pii: 10.1038/s41433-022-02147-7
pmc: PMC10170101
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1416-1423

Subventions

Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States

Informations de copyright

© 2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Références

Am J Ophthalmol. 2008 Oct;146(4):486-8
pubmed: 18804561
Ocul Immunol Inflamm. 2020 Sep 30;28(sup1):38-48
pubmed: 30156979
J Infect Dis. 2011 Nov 15;204 Suppl 4:S1120-9
pubmed: 21996694
Retina. 2019 Aug;39(8):1623-1630
pubmed: 29697588
BMJ. 1995 Aug 5;311(7001):376-80
pubmed: 7640549
Health Technol Assess. 2007 Jan;11(3):1-196
pubmed: 17266837
Surv Ophthalmol. 2007 Nov-Dec;52(6):561-87
pubmed: 18029267
Ocul Immunol Inflamm. 2018;26(2):208-216
pubmed: 27379384
Ophthalmology. 2013 Sep;120(9):1761-8
pubmed: 23664179
Br J Ophthalmol. 2014 Aug;98(8):999-1000
pubmed: 24642664
Ocul Immunol Inflamm. 2009 Sep-Oct;17(5):351-5
pubmed: 19831571
Br J Ophthalmol. 2017 Jan;101(1):6-9
pubmed: 27815270
Ocul Immunol Inflamm. 2015 Feb;23(1):14-24
pubmed: 25615807
MMWR Morb Mortal Wkly Rep. 2019 Jun 21;68(24):552-553
pubmed: 31220054
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4162-4171
pubmed: 30120485
Acta Ophthalmol. 2013 Nov;91(7):e550-5
pubmed: 23694755
AJR Am J Roentgenol. 2008 Sep;191(3):834-44
pubmed: 18716117
Ocul Immunol Inflamm. 2015 Feb;23(1):40-6
pubmed: 25615809
Thorax. 2002 Sep;57(9):804-9
pubmed: 12200526
Pediatrics. 2019 Feb;143(2):
pubmed: 30606746
Ocul Immunol Inflamm. 2015 Feb;23(1):32-9
pubmed: 25615808
JAMA Ophthalmol. 2017 Dec 1;135(12):1318-1327
pubmed: 29075752
Ocul Immunol Inflamm. 2020 Sep 30;28(sup1):85-95
pubmed: 32250731
Retina. 2014 Jun;34(6):1247-52
pubmed: 24285246
Medicine (Baltimore). 1997 Jan;76(1):53-61
pubmed: 9064488
J Clin Diagn Res. 2016 Mar;10(3):NR01-3
pubmed: 27134908
Clin Exp Ophthalmol. 2021 Mar;49(2):146-160
pubmed: 33429468
J Ophthalmic Inflamm Infect. 2014 Feb 01;4(1):3
pubmed: 24485195
Ocul Immunol Inflamm. 2020 Sep 30;28(sup1):74-84
pubmed: 31821096
Can J Ophthalmol. 2006 Dec;41(6):737-40
pubmed: 17224956
Ocul Immunol Inflamm. 2015 Feb;23(1):7-13
pubmed: 25314361
Anesth Analg. 2015 May;120(5):1056-1059
pubmed: 25899272
Int Ophthalmol. 1995-1996;19(5):293-8
pubmed: 8864813
MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25
pubmed: 20577159
Ophthalmology. 2021 Feb;128(2):277-287
pubmed: 32603726
Ophthalmology. 2021 Feb;128(2):266-276
pubmed: 32115264
Ocul Immunol Inflamm. 2019;27(3):465-473
pubmed: 29261089
Retina. 2017 Jan;37(1):112-117
pubmed: 27491042
Am J Ophthalmol. 2010 Apr;149(4):562-70
pubmed: 20149341
Ocul Immunol Inflamm. 2015 Feb;23(1):25-31
pubmed: 25019973
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316
Am J Ophthalmol. 2021 Aug;228:142-151
pubmed: 33845014

Auteurs

Rupesh Agrawal (R)

National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore. rupesh_agrawal@ttsh.com.sg.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. rupesh_agrawal@ttsh.com.sg.
Duke NUS Medical School, Singapore, Singapore. rupesh_agrawal@ttsh.com.sg.
Singapore Eye Research Institute, Singapore, Singapore. rupesh_agrawal@ttsh.com.sg.
National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK. rupesh_agrawal@ttsh.com.sg.

Zhang Ludi (Z)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

Bjorn K Betzler (BK)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Ilaria Testi (I)

National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK.

Sarakshi Mahajan (S)

St Joseph Mercy Hospital, Oakland, Pontiac, MI, USA.

Andres Rousellot (A)

Ciudad Autónoma de Buenos Aires, Consultorios Oftalmológicos Benisek-Ascarza, Buenos Aires, Argentina.

John H Kempen (JH)

Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear/Harvard Medical School, Boston, MA, USA.
Sight for Souls, Fort Myers, FL, USA.
Department of Ophthalmology, Addis Ababa University, Addis Ababa, Ethiopia.
MyungSung Christian Medical Center (MCM) Eye Unit, MCM General Hospital, MyungSung Medical School, Addis Ababa, Ethiopia.

Justine R Smith (JR)

Flinders University College of Medicine & Public Health, Adelaide, SA, Australia.
Queensland Eye Institute, Brisbane, QLD, Australia.

Peter McCluskey (P)

Save Sight Institute, Department of Ophthalmology, The University of Sydney, Sydney, NSW, Australia.

Quan Dong Nguyen (QD)

Byers Eye Institute, Stanford Medical School, Palo alto, CA, USA.

Carlos Pavesio (C)

National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK.

Vishali Gupta (V)

Advanced Eye Centre, Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. vishalisara@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH